First Header Logo Second Header Logo

Connection

Michael Shapiro to Cardiovascular Diseases

Back to Details
This is a "connection" page, showing publications Michael Shapiro has written about Cardiovascular Diseases.
Michael Shapiro
Connection Strength
9.929
Cardiovascular Diseases
  1. Hammoud A, Chen H, Ivanov A, Yeboah J, Nasir K, Cainzos-Achirica M, Bertoni A, Khan SU, Blaha M, Herrington D, Shapiro MD. Implications of Social Disadvantage Score in Cardiovascular Outcomes and Risk Assessment: Findings From the Multi-Ethnic Study of Atherosclerosis. Circ Cardiovasc Qual Outcomes. 2023 Jul; 16(7):e009304.
    View in: PubMed
    Score: 0.506
  2. Rikhi R, Shapiro MD. Assessment of Atherosclerotic Cardiovascular Disease Risk in Primary Prevention. J Cardiopulm Rehabil Prev. 2022 Nov 01; 42(6):397-403.
    View in: PubMed
    Score: 0.483
  3. Rikhi R, Hammoud A, Ashburn N, Snavely AC, Michos ED, Chevli P, Tsai MY, Herrington D, Shapiro MD. Relationship of low-density lipoprotein-cholesterol and lipoprotein(a) to cardiovascular risk: The Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis. 2022 Dec; 363:102-108.
    View in: PubMed
    Score: 0.481
  4. McNavish DE, German CA, Shapiro MD. Should a Statin be Given to All Hypertensive Patients? Curr Hypertens Rep. 2022 Jan; 24(1):21-27.
    View in: PubMed
    Score: 0.458
  5. Mahmood T, Shapiro MD. The Questions on Everyone's Mind: What is and Why Do We Need Preventive Cardiology? Methodist Debakey Cardiovasc J. 2021; 17(4):8-14.
    View in: PubMed
    Score: 0.448
  6. Al Rifai M, Shapiro MD. A multifaceted approach for management of prediabetes and its associated cardiovascular risk. Diabetes Metab Res Rev. 2020 09; 36(6):e3314.
    View in: PubMed
    Score: 0.404
  7. Shapiro MD, Maron DJ, Morris PB, Kosiborod M, Sandesara PB, Virani SS, Khera A, Ballantyne CM, Baum SJ, Sperling LS, Bhatt DL, Fazio S. Preventive Cardiology as a Subspecialty of Cardiovascular Medicine: JACC Council Perspectives. J Am Coll Cardiol. 2019 10 15; 74(15):1926-1942.
    View in: PubMed
    Score: 0.391
  8. Wójcik C, Shapiro MD. Bridging the Gap Between Cardiology and Family Medicine. Circulation. 2019 08 27; 140(9):709-711.
    View in: PubMed
    Score: 0.388
  9. Warden BA, Fazio S, Shapiro MD. The PCSK9 revolution: Current status, controversies, and future directions. Trends Cardiovasc Med. 2020 04; 30(3):179-185.
    View in: PubMed
    Score: 0.381
  10. Wójcik C, Shapiro MD. Translating AHA/ACC cholesterol guidelines into meaningful risk reduction. J Fam Pract. 2019 05; 68(4):206;210;212;214;217;221B.
    View in: PubMed
    Score: 0.379
  11. Warden BA, Minnier J, Watts GF, Fazio S, Shapiro MD. Impact of PCSK9 inhibitors on plasma lipoprotein(a) concentrations with or without a background of niacin therapy. J Clin Lipidol. 2019 Jul - Aug; 13(4):580-585.
    View in: PubMed
    Score: 0.379
  12. Kaufman TM, Fazio S, Shapiro MD. Brief Commentary: Marijuana and Cardiovascular Disease-What Should We Tell Patients? Ann Intern Med. 2019 01 15; 170(2):119-120.
    View in: PubMed
    Score: 0.371
  13. Kaufman TM, Warden BA, Minnier J, Miles JR, Duell PB, Purnell JQ, Wojcik C, Fazio S, Shapiro MD. Application of PCSK9 Inhibitors in Practice. Circ Res. 2019 01 04; 124(1):32-37.
    View in: PubMed
    Score: 0.371
  14. Shapiro MD, Miles J, Tavori H, Fazio S. Diagnosing Resistance to a Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor. Ann Intern Med. 2018 03 06; 168(5):376-379.
    View in: PubMed
    Score: 0.344
  15. Shapiro MD, Fazio S. Setting the Agenda for Preventive Cardiology. Circ Res. 2017 07 21; 121(3):211-213.
    View in: PubMed
    Score: 0.335
  16. Shapiro MD, Fazio S. Dyslipidaemia: The PCSK9 adventure - humanizing extreme LDL lowering. Nat Rev Cardiol. 2017 06; 14(6):319-320.
    View in: PubMed
    Score: 0.330
  17. Surma S, Shapiro MD, Banach M. Breaking new ground in lipid management: Insights from the 2024 American College of Cardiology Scientific Sessions. Pharmacol Res. 2024 Jul; 205:107246.
    View in: PubMed
    Score: 0.135
  18. Jaspan VN, Greenberg GS, Parihar S, Park CM, Somers VK, Shapiro MD, Lavie CJ, Virani SS, Slipczuk L. The Role of Sleep in Cardiovascular Disease. Curr Atheroscler Rep. 2024 Jul; 26(7):249-262.
    View in: PubMed
    Score: 0.135
  19. Shapiro MD, German CA. Early Inclisiran Use in Atherosclerotic Cardiovascular Disease: Overcoming Therapeutic Inertia. J Am Coll Cardiol. 2024 May 21; 83(20):1953-1956.
    View in: PubMed
    Score: 0.135
  20. Masrouri S, Shapiro MD, Khalili D, Hadaegh F. Impact of coronary artery calcium on mortality and cardiovascular events in metabolic syndrome and diabetes among younger adults. Eur J Prev Cardiol. 2024 Apr 18; 31(6):744-753.
    View in: PubMed
    Score: 0.134
  21. Minhas AMK, Gupta K, Jain V, Kakar TS, Merchant AT, Shapiro MD, Abushamat LA, Nambi V, Virani SS. Trends in cardiovascular mortality in the United States from 1968 to 2019: analysis of the CDC WONDER database. Eur J Prev Cardiol. 2024 Mar 27; 31(5):e33-e35.
    View in: PubMed
    Score: 0.133
  22. Minhas AMK, Kewcharoen J, Hall ME, Warraich HJ, Greene SJ, Shapiro MD, Michos ED, Sauer AJ, Abramov D. Temporal Trends in Substance Use and Cardiovascular Disease-Related Mortality in the United States. J Am Heart Assoc. 2024 Jan 16; 13(2):e030969.
    View in: PubMed
    Score: 0.131
  23. Muluk P, Zhu J, Thoma F, Hay E, Marroquin O, Makani A, Aiyer A, Nasir K, Gulati M, Shapiro MD, Mulukutla S, Saeed A. Impact of Guideline-Directed Statin Intervention for Primary Prevention in Patients With Diabetes. Diabetes Care. 2023 Dec 01; 46(12):2273-2277.
    View in: PubMed
    Score: 0.130
  24. Caldarera T, Ponir C, Seals A, Penmetsa M, Ip E, German CA, Virani SS, Saha A, Bosworth HB, Moore JB, Shapiro MD, Pokharel Y. Clinicians' self-reported efficacy in cardiovascular prevention practice in the southeastern United States. Future Cardiol. 2023 Sep; 19(12):593-604.
    View in: PubMed
    Score: 0.130
  25. Ponir C, Annabathula R, Caldarera T, Penmetsa M, Seals A, Saha A, Moore JB, Bosworth HB, Ip EH, Shapiro MD, Pokharel Y. Availability of Specialty Services for Cardiovascular Prevention Practice in the Southeastern United States. South Med J. 2023 Nov; 116(11):848-856.
    View in: PubMed
    Score: 0.130
  26. Patel KV, Budoff MJ, Valero-Elizondo J, Lahan S, Ali SS, Taha MB, Blaha MJ, Blankstein R, Shapiro MD, Pandey A, Arias L, Feldman T, Cury RC, Cainzos-Achirica M, Shah SH, Ziffer JA, Fialkow J, Nasir K. Coronary Atherosclerosis Across the Glycemic Spectrum Among Asymptomatic Adults: The Miami Heart Study at Baptist Health South Florida. Circ Cardiovasc Imaging. 2023 Oct; 16(10):e015314.
    View in: PubMed
    Score: 0.129
  27. Kazibwe R, Chevli PA, Evans JK, Allison M, Michos ED, Wood AC, Ding J, Shapiro MD, Mongraw-Chaffin M. Association Between Alcohol Consumption and Ectopic Fat in the Multi-Ethnic Study of Atherosclerosis. J Am Heart Assoc. 2023 Sep 19; 12(18):e030470.
    View in: PubMed
    Score: 0.128
  28. Masrouri S, Tamehri Zadeh SS, Pishgahi M, Azizi F, Shapiro MD, Hadaegh F. Kidney function decline is associated with mortality events: over a decade of follow-up from Tehran Lipid and Glucose Study. J Nephrol. 2024 Jan; 37(1):107-118.
    View in: PubMed
    Score: 0.128
  29. Krittanawong C, Maitra NS, El-Sherbini AH, Shah N, Lavie CJ, Shapiro MD, Virani SS. Lipoprotein(a) in clinical practice: A guide for the clinician. Prog Cardiovasc Dis. 2023; 79:28-36.
    View in: PubMed
    Score: 0.127
  30. Zhou XD, Targher G, Byrne CD, Somers V, Kim SU, Chahal CAA, Wong VW, Cai J, Shapiro MD, Eslam M, Steg PG, Sung KC, Misra A, Li JJ, Brotons C, Huang Y, Papatheodoridis GV, Sun A, Yilmaz Y, Chan WK, Huang H, Méndez-Sánchez N, Alqahtani SA, Cortez-Pinto H, Lip GYH, de Knegt RJ, Ocama P, Romero-Gomez M, Fudim M, Sebastiani G, Son JW, Ryan JD, Ikonomidis I, Treeprasertsuk S, Pastori D, Lupsor-Platon M, Tilg H, Ghazinyan H, Boursier J, Hamaguchi M, Nguyen MH, Fan JG, Goh GB, Al Mahtab M, Hamid S, Perera N, George J, Zheng MH. An international multidisciplinary consensus statement on MAFLD and the risk of CVD. Hepatol Int. 2023 Aug; 17(4):773-791.
    View in: PubMed
    Score: 0.125
  31. Mehta A, Dixon DL, Saeed A, Kelly MS, Gulati M, Shapiro MD, Sperling LS, Virani SS. With Current Safety and Efficacy Data, Should Statins Be Made Available as Nonprescription Over-the-Counter Drugs? Curr Cardiol Rep. 2023 May; 25(5):423-430.
    View in: PubMed
    Score: 0.124
  32. Acquah I, Hagan K, Javed Z, Taha MB, Valero-Elizondo J, Nwana N, Yahya T, Sharma G, Gulati M, Hammoud A, Shapiro MD, Blankstein R, Blaha MJ, Cainzos-Achirica M, Nasir K. Social Determinants of Cardiovascular Risk, Subclinical Cardiovascular Disease, and Cardiovascular Events. J Am Heart Assoc. 2023 Mar 21; 12(6):e025581.
    View in: PubMed
    Score: 0.124
  33. Zhou XD, Cai J, Targher G, Byrne CD, Shapiro MD, Sung KC, Somers VK, Chahal CAA, George J, Chen LL, Zhou Y, Zheng MH. Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention. Cardiovasc Diabetol. 2022 Dec 03; 21(1):270.
    View in: PubMed
    Score: 0.122
  34. Al Rifai M, Szklo M, Patel J, Blaha MJ, Ballantyne CM, Bittner V, Morris P, McEvoy JW, Shapiro MD, Al-Mallah MH, Greenland P, Virani SS. Statin Use and Risk of Diabetes by Subclinical Atherosclerosis Burden (from a Multi-Ethnic Study of Atherosclerosis Report). Am J Cardiol. 2022 Dec 01; 184:7-13.
    View in: PubMed
    Score: 0.120
  35. Alfaddagh A, Kapoor K, Dardari ZA, Bhatt DL, Budoff MJ, Nasir K, Miller M, Welty FK, Miedema MD, Shapiro MD, Tsai MY, Blumenthal RS, Blaha MJ. Omega-3 fatty acids, subclinical atherosclerosis, and cardiovascular events: Implications for primary prevention. Atherosclerosis. 2022 Jul; 353:11-19.
    View in: PubMed
    Score: 0.118
  36. Tardif JC, Karwatowska-Prokopczuk E, Amour ES, Ballantyne CM, Shapiro MD, Moriarty PM, Baum SJ, Hurh E, Bartlett VJ, Kingsbury J, Figueroa AL, Alexander VJ, Tami J, Witztum JL, Geary RS, O'Dea LSL, Tsimikas S, Gaudet D. Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. Eur Heart J. 2022 Apr 06; 43(14):1401-1412.
    View in: PubMed
    Score: 0.116
  37. Virani SS, Koschinsky ML, Maher L, Mehta A, Orringer CE, Santos RD, Shapiro MD, Saseen JJ. Global think tank on the clinical considerations and management of lipoprotein(a): The top questions and answers regarding what clinicians need to know. Prog Cardiovasc Dis. 2022; 73:32-40.
    View in: PubMed
    Score: 0.114
  38. German CA, Fanning J, Singleton MJ, Shapiro MD, Brubaker PH, Bertoni AG, Yeboah J. Physical Activity, Coronary Artery Calcium, and Cardiovascular Outcomes in the Multi-Ethnic Study of Atherosclerosis (MESA). Med Sci Sports Exerc. 2022 May 01; 54(5):800-806.
    View in: PubMed
    Score: 0.114
  39. Board C, Kelly MS, Shapiro MD, Dixon DL. PCSK9 Inhibitors in Secondary Prevention-An Opportunity for Personalized Therapy. J Cardiovasc Pharmacol. 2020 05; 75(5):410-420.
    View in: PubMed
    Score: 0.102
  40. German CA, Shapiro MD. Small Interfering RNA Therapeutic Inclisiran: A New Approach to Targeting PCSK9. BioDrugs. 2020 Feb; 34(1):1-9.
    View in: PubMed
    Score: 0.100
  41. Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, Tardif JC, Baum SJ, Steinhagen-Thiessen E, Shapiro MD, Stroes ES, Moriarty PM, Nordestgaard BG, Xia S, Guerriero J, Viney NJ, O'Dea L, Witztum JL. Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. N Engl J Med. 2020 01 16; 382(3):244-255.
    View in: PubMed
    Score: 0.099
  42. Warden BA, Shapiro MD, Fazio S. The Role of the Clinical Pharmacist in a Preventive Cardiology Practice. Ann Pharmacother. 2019 12; 53(12):1214-1219.
    View in: PubMed
    Score: 0.096
  43. Shapiro MD, Tavori H, Fazio S. PCSK9: From Basic Science Discoveries to Clinical Trials. Circ Res. 2018 05 11; 122(10):1420-1438.
    View in: PubMed
    Score: 0.089
  44. Sun BC, Laurie A, Fu R, Ferencik M, Shapiro M, Lindsell CJ, Diercks D, Hoekstra JW, Hollander JE, Kirk JD, Peacock WF, Anantharaman V, Pollack CV. Comparison of the HEART and TIMI Risk Scores for Suspected Acute Coronary Syndrome in the Emergency Department. Crit Pathw Cardiol. 2016 Mar; 15(1):1-5.
    View in: PubMed
    Score: 0.076
  45. Kaul S, Rothney MP, Peters DM, Wacker WK, Davis CE, Shapiro MD, Ergun DL. Dual-energy X-ray absorptiometry for quantification of visceral fat. Obesity (Silver Spring). 2012 Jun; 20(6):1313-8.
    View in: PubMed
    Score: 0.057
  46. Minhas AMK, Mathew RO, Sperling LS, Nambi V, Virani SS, Navaneethan SD, Shapiro MD, Abramov D. Prevalence of the Cardiovascular-Kidney-Metabolic Syndrome in the United States. J Am Coll Cardiol. 2024 May 07; 83(18):1824-1826.
    View in: PubMed
    Score: 0.033
  47. Duell PB, Gidding SS, Andersen RL, Knickelbine T, Anderson L, Gianos E, Shrader P, Kindt I, O'Brien EC, McCann D, Hemphill LC, Ahmed CD, Martin SS, Larry JA, Ahmad ZS, Kullo IJ, Underberg JA, Guyton J, Thompson P, Wilemon K, Roe MT, Rader DJ, Cuchel M, Linton MF, Shapiro MD, Moriarty PM, Knowles JW. Longitudinal low density lipoprotein cholesterol goal achievement and cardiovascular outcomes among adult patients with familial hypercholesterolemia: The CASCADE FH registry. Atherosclerosis. 2019 10; 289:85-93.
    View in: PubMed
    Score: 0.024
  48. Amrock SM, Duell PB, Knickelbine T, Martin SS, O'Brien EC, Watson KE, Mitri J, Kindt I, Shrader P, Baum SJ, Hemphill LC, Ahmed CD, Andersen RL, Kullo IJ, McCann D, Larry JA, Murray MF, Fishberg R, Guyton JR, Wilemon K, Roe MT, Rader DJ, Ballantyne CM, Underberg JA, Thompson P, Duffy D, Linton MF, Shapiro MD, Moriarty PM, Knowles JW, Ahmad ZS. Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FH™ patient registry. Atherosclerosis. 2017 Dec; 267:19-26.
    View in: PubMed
    Score: 0.021
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.